Maplirpacept + Standard Therapies for Blood Cancers
(TTI-622-01 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new medicine called maplirpacept (also known as TTI-622) for individuals with various blood cancers, such as lymphoma, multiple myeloma, and acute myeloid leukemia (AML). The goal is to determine if maplirpacept, alone or with other cancer medicines, is safe and effective in controlling these cancers. In the first part (phase 1a), the medicine is administered alone to identify the safest dose. The second part (phase 1b) evaluates how well maplirpacept works with other treatments. This trial might be suitable for those with relapsed blood cancer or newly diagnosed AML who have no other treatment options. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new medicine.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have taken any investigational or anticancer drugs within 14 days before starting the study treatment.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that maplirpacept (also known as PF-07901801) is generally well-tolerated in clinical trials. Studies indicate that this experimental medicine is safe for individuals with various blood cancers. Reports suggest it might also be safe to use maplirpacept alongside other cancer treatments. However, the safety and effectiveness of maplirpacept remain under investigation. As with any trial, side effects may occur, and participants receive close monitoring to ensure their safety.12345
Why are researchers excited about this trial's treatments?
Researchers are excited about maplirpacept because it offers a novel approach to treating blood cancers, such as multiple myeloma and acute myeloid leukemia. Unlike traditional therapies that often target cancer cells directly, maplirpacept works by enhancing the immune system's ability to recognize and destroy cancer cells. This is achieved through its unique action as a CD47-SIRPα pathway inhibitor, which essentially "unmasks" cancer cells, allowing the immune system to attack them more effectively. Additionally, maplirpacept is being tested both as a standalone treatment and in combination with other drugs, like isatuximab and venetoclax, potentially leading to more versatile and effective treatment options for patients.
What evidence suggests that this trial's treatments could be effective for blood cancers?
Research shows that maplirpacept (PF-07901801), which participants in this trial may receive, may help treat blood cancers like multiple myeloma, acute myeloid leukemia (AML), and diffuse large B-cell lymphoma. Lab studies have found that maplirpacept helps the immune system better locate and destroy cancer cells. It enhances a process called phagocytosis, where immune cells "eat" cancer cells. This effect has appeared in studies on both multiple myeloma and AML cells. Early results suggest it might fight cancer, but further research is needed to confirm its effectiveness.15678
Who Is on the Research Team?
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Are You a Good Fit for This Trial?
Adults with advanced blood cancers like lymphoma, leukemia, and multiple myeloma who've had their disease worsen after standard treatments can join. They need a tissue sample for research, good liver/kidney/blood function, and an ECOG score of 0-2 (which measures cancer patients' daily living abilities). People can't join if they've recently had other cancer drugs or major surgery, have brain involvement by the cancer, recent radiation therapy or stem cell transplant complications.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Phase 1a Treatment
Dose-escalation phase where participants receive maplirpacept (PF-07901801) as a single agent to determine safety and maximum tolerated dose.
Phase 1b Treatment
Participants receive maplirpacept (PF-07901801) in combination with other anticancer medicines to evaluate safety and efficacy.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Quality-of-Life Assessment
- TTI-622
Find a Clinic Near You
Who Is Running the Clinical Trial?
Trillium Therapeutics Inc.
Lead Sponsor
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University
Trillium Therapeutics, Inc., a Pfizer Company
Collaborator